Author Interviews, Brain Injury, Cannabis / 07.05.2024

MedicalResearch.com Interview with: Pamela Maher, PhD Research Professor Cellular Neurobiology Laboratory SALK Institute for Biologic Studies La Jolla California   MedicalResearch.com: What is the background for this study? Response: Several years ago, we tested several different cannabinoids for protection against the oxytosis/ferroptosis regulated cell death pathway and found CBN (cannabinol) to be one of the most effective. While THC (tetrahydrocannabinol) and CBD (cannabidol) were also quite protective, we wanted to pursue non-psychoactive cannabinoids. Since we are interested in maintaining brain function in the context of aging and disease, we thought that a psychoactive compound could be problematic. In addition, there was already a lot of work on CBD, so we thought we could learn more and contribute more to the field by studying CBN. (more…)
Author Interviews, Cannabis / 18.04.2024

MedicalResearch.com Interview with: Amy Kennalley, MBS First Year Medical Student Department of Medical Education Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study Response: The legalization of medical marijuana (MMJ) and the number of qualifying conditions are expanding across the USA, emphasizing the need to understand the implications of MMJ dispensary distribution for equitable access. Pennsylvania (PA) legalized MMJ in 2016, with the first dispensary opening its doors in 2018. The state currently recognizes 24 medical conditions for MMJ use, including six for which there is insufficient or no evidence for their efficacy as a treatment. Prior research suggests that there is a link between proximity to dispensaries and overall MMJ use. However, a gap exists in our understanding of how dispensary locations might be associated with the specific qualifying conditions for which individuals receive their certification. In response to this knowledge gap, our study delved into the medical marijuana dispensary access in PA and explored associations with both MMJ certifications and the community demographics. Utilizing data from the Pennsylvania Department of Health, we investigated how proximity to MMJ dispensaries related to the proportion of individuals certified for MMJ use within a specific area or Zip Code Tabulation Area. Additionally, we analyzed the proportion of certifications for conditions with varying levels of evidence supporting the efficacy of MMJ. This pioneering study represents the first of its kind in PA, shedding light on the association between MMJ dispensary locations and certifications. Likewise, it is the first in the US to investigate the link between dispensary locations and specific qualifying conditions. By examining these dynamics, we aim to contribute vital insights to inform policy and practice, ensuring equitable access to MMJ treatment for individuals with diverse medical needs. (more…)
Addiction, Author Interviews, Cancer Research, Cannabis / 23.03.2024

MedicalResearch.com Interview with: Brian J. Piper, PhD Associate Professor of Neuroscience Geisinger Commonwealth School of Medicine Scranton PA 18411 MedicalResearch.com: What is the background for this study? Response: Many cancer patients use marijuana to treat pain, nausea, or anxiety, often without communicating this with their health care providers. Two observational studies (1, 2) from a single institution in Israel purporting to find a dangerous drug interaction between medical cannabis and immunotherapy have been cited hundreds of times, including by clinical practice guidelines. The cannabinoid CB2 receptor is found on immune tissues so it is biologically possible that marijuana could make immunotherapies like nivolumab less effective. However, there were anonymous reports on PubPeer (3-5) of many irregularities in the data-analysis. If there were unappreciated differences on other important variables at baseline besides subsequent cannabis use, this could change the interpretation of these influential reports (1, 2). This investigation involved attempting to repeat and verify the data-analysis. (more…)
Accidents & Violence, Aging, Author Interviews, Cannabis, JAMA / 19.01.2024

MedicalResearch.com Interview with: Patricia Di Ciano, PhD Scientist, Institute for Mental Health Policy Research, Centre for Addiction and Mental Health Assistant Professor, Department of Pharmacology and Toxicology University of Toronto Campbell Family Mental Health Research Institute Collaborative Program in Neuroscience MedicalResearch.com: What is the background for this study? Response: It is now fairly well established that cannabis has a detrimental effect on driving. The most consistently reported effect of cannabis on driving is to increase ‘weaving’ on the road. We know that cannabis use is on the rise in people over 65 years of age. In fact, over the past few years cannabis use is increasing the most in this age group. Despite this, there are few studies of the effects of cannabis on people over 65; most studies have been conducted on younger adults. We know that there are important age-related changes in the way the body works that may alter the impact of cannabis on the body. Also, older adults may have more experience with cannabis and this can change the effects of cannabis. (more…)
Author Interviews, Cannabis, Medical Imaging, Pulmonary Disease / 10.12.2023

MedicalResearch.com Interview with: Jessie Kang, MD, FRCPC Assistant professor Department of Diagnostic Radiology Faculty of Medicine Dalhousie University   MedicalResearch.com: What is the background for this study?
  • Marijuana is the most widely used illicit psychoactive substance in the world.
  • Use has increased in Canada since legalization of non-medical marijuana in 2018.
  • It is commonly believed that smoking marijuana is not harmful to the lungs. There is an abundance of established research that identifies the harms of cigarette smoking. In contrast, very little is known about the effects of marijuana smoking, and even less research has been done on the combined effects of smoking marijuana and cigarettes.
To determine the effects of marijuana and cigarette smoking, we examined the chest CT images of four patient groups: non-smokers, cigarette smokers, marijuana smokers, and combined marijuana and cigarette smokers. Marijuana smokers included in the study had smoked marijuana at least four times a month for two years. Patients who ingested marijuana via edibles or oral drops were excluded from the study. (more…)
Author Interviews, Cannabis / 30.08.2023

MedicalResearch.com Interview with: Luke Cavanah, BS Geisinger Commonwealth School of Medicine Scranton, PA MedicalResearch.com: What is the background for this study? Response: It is well-known that schedule II stimulants, which are those that are highly addictive and include amphetamine, methylphenidate, and lisdexamfetamine, have had increasing use and misuse in the US. Despite understanding the presence of this phenomenon, the reason for it is poorly understood. The purpose of this study was to see if rising rates of schedule II stimulants are related to the legalization of medical marijuana. We were interested in this because schedule II stimulants are primarily used as the treatment for attention-deficit hyperactivity disorder (ADHD), chronic cannabis use has been demonstrated to cause neurocognitive deficits resembling that of ADHD, and the conditions have been shown to affect similar brain regions. (more…)
Addiction, Author Interviews, Cannabis, Mental Health Research / 12.07.2023

MedicalResearch.com Interview with: Jessica Kruger PhD Clinical Associate Professor of Community Health and Health Behavior University at Buffalo School of Public Health and Health Professions MedicalResearch.com: What is the background for this study? Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products. The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT. (more…)
Anesthesiology, Author Interviews, Cannabis, JAMA, Opiods, Surgical Research, University Texas / 10.07.2023

MedicalResearch.com Interview with: Paul Potnuru, MD Assistant Professor Anesthesiology, Critical Care and Pain Medicine The John P. and Kathrine G. McGovern Medical School The University of Texas Health Science Center at Houston UTHealth MedicalResearch.com: What is the background for this study? Response: The use of cannabis is on the rise in the United States, as it becomes increasingly legally accepted and is viewed as harmless. Furthermore, the potency of cannabis is steadily increasing over time. There is some evidence from previous studies that compared to non-users, cannabis users require more anesthetics, have higher pain after surgery that requires more opioids, and have an increased risk of postoperative nausea and vomiting. Given this context of increased usage and potential risks during surgery, we conducted a study to examine the impact of cannabis use on patients undergoing surgery. (more…)
Author Interviews, Cannabis / 07.07.2023

MedicalResearch.com Interview with: Edward Liu, BA Second year medical student Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA MedicalResearch.com: What is the background for this study? Response: The use pattern of two FDA approved cannabinoids, dronabinol (Marinol) and cannabidiol (Epidiolex) has not been previously studied. Dronabinol has been approved in the United States since 1985 for chemotherapy induced nausea as well as vomiting and HIV-induced anorexia,1,2 whereas cannabidiol has been approved since 2018 to treat childhood epileptic disorders, Lennox-Gastaut and Dravet syndrome.3 This longitudinal study examined Medicaid claims between 2016-2020 for these two prescription cannabinoids to better comprehend the state-level pharmacoepidemiologic trends and distribution of these drugs in US Medicaid amidst the increasing use of non-pharmaceutical formulations of cannabis. (more…)
Author Interviews, Cannabis, JAMA, OBGYNE, Pediatrics / 26.06.2023

MedicalResearch.com Interview with: Alex P. Miller, PhD TranSTAR T32 Postdoctoral Fellow Department of Psychiatry Washington University School of Medicine St. Louis, MO   MedicalResearch.com: What is the background for this study? Response: Adolescent cannabis use is increasing in the United States. Prior research suggests that people who start using cannabis earlier are more likely to engage in problematic use and also experience greater mental health challenges and socioeconomic disadvantages overall. For example, children who begin using cannabis early are more likely to have behavioral problems and disorders and are more less likely to complete school. In our study, we used data from the Adolescent Brain Cognitive Development (ABCD) Study, which is following nearly 12,000 kids across the nation to track behavior and brain development as well as health from middle childhood to young adulthood. We looked at what factors are associated with the initiation of cannabis use by age 12-14. (more…)
Author Interviews, Cannabis / 24.05.2023

MedicalResearch.com Interview with:   Tara M Lovestead, PhD, (She/her/hers) Group Leader | Fluid Characterization Group Applied Chemicals and Materials Division National Institute of Standards and Technology Gaithersburg, MD   MedicalResearch.com: What is the background for this study? Response: In 2012, when cannabis was decriminalized for adult recreational and medical use in Colorado, I started thinking about how a cannabis breathalyzer could work. I knew that an alcohol breathalyzer model would be pursued for a field sobriety test, but also knew that THC, the main psychoactive compound in cannabis, was a completely different animal, chemically speaking, than ethanol, the intoxicant in alcohol. I began by measuring the vapor pressure of THC and determined that it is a million times less volatile than ethanol. This is why the main strategy for measuring THC in breath is based on collecting breath aerosols with filters (ethanol is measured as a vapor in breath and does not need to be “collected”). My colleague, Dr. Kavita Jeerage and I began working together to design a study using a simple device that samples breath aerosols that hadn’t been used before. We designed this as a small study to piggyback on a larger study with our collaborator Prof. Cinnamon Bidwell at the University of Colorado, Boulder. Bidwell’s experience studying the effects of legal market cannabis product use on psychology and behavior was leveraged to launch the pilot study. (more…)
Author Interviews, Cannabis, Pharmacology, Tobacco Research / 08.03.2023

MedicalResearch.com Interview with: Philip Lazarus, PhD Boeing Distinguished Professor, Pharmaceutical Sciences Professor, Dept of Pharmaceutical Sciences College of Pharmacy and Pharmaceutical Sciences Washington State University Spokane, WA 99210   MedicalResearch.com: What is the background for this study? Response: Smoking and tobacco use remains a major health issue. Smokers use cigarette over the course of the day because the levels of nicotine, the addictive agent in cigarettes and other forms of tobacco, dimmish with time in the bloodstream due to the breakdown of nicotine by enzymes in the body. By inhibiting the breakdown of nicotine in smokers, one would expect that the levels of nicotine would remain higher after smoking a single cigarette, and that these individuals may not require lighting up another cigarette so quickly, reducing the number of cigarettes smoked over the course of a day. This could have a profound effect on reducing the overall harm incurred from smoking or from using other forms of tobacco. In a single previous study, smokers who used a CBD inhaler exhibited a 40% reduction in cigarette use. In addition, while cannabis users are often smokers, previous studies have indicated that they smoke less cigarettes than non-cannabis-using cigarette smokers. In previous studies published in 2021, we found that major cannabinoids present in cannabis like THC and CBD inhibit major metabolizing enzymes in our body, including several that are important in drug metabolism. We hypothesized that CBD and its major active metabolite, 7-hydroxy (OH)-CBD, may also be inhibiting one or more of the enzymes important in the metabolism (or breakdown) of nicotine. (more…)
Author Interviews, Cannabis / 27.12.2022

You might have heard good things about CBD oil. You heard that it can assist with numerous conditions and symptoms. However, what you heard might have been simply hearsay and not necessarily proven fact. What you want to know is the science-backed health benefits about CBD oil from actual studies and research, which we provide below.
  1. Alleviate Stress & Anxiety
Stress is something we all experience at some point in time. The worse it gets, the more debilitating it can be and the more it can, in turn, affect our daily lives. A study found that use of CBD oil can not only help one combat excess stress, but it’s also effective for those who struggle with anxiety. (more…)
Addiction, Alcohol, Author Interviews, Cannabis, Education, JAMA, Pediatrics, Social Issues, UCLA / 06.10.2022

MedicalResearch.com Interview with: Mitchell Wong, MD PhD Professor of Medicine Executive Vice Chair for Research Training Department of Medicine Executive Co-Director, Specialty Training and Advanced Research (STAR) Program Director, UCLA CTSI KL2 Program UCLA Division of General Internal Medicine and Health Services Research Los Angeles, CA 90024 MedicalResearch.com: What is the background for this study? Response: It is estimated that social factors like poverty, education, and housing have a large impact on health. Yet, there are few interventions that exist to directly address those issues.  Schools are a promising solution since society already invests heavily in education and schools are an everyday part of most children’s lives. (more…)
Author Interviews, Cannabis, JAMA, Pediatrics / 07.01.2022

MedicalResearch.com Interview with: Daniel Myran, MD, MPH, CCFP, FRCPC Family and Public Health and Preventive Medicine Physician CIHR Fellow, Ottawa Hospital Research Institute Department of Family Medicine Innovation Fellow University of Ottawa MedicalResearch.com: What is the background for this study? Response: Canada legalized recreational, or non-medical, cannabis in October 2018. Canada took phased approach to legalization initially only allowing flower-based cannabis products and oils and after one year permitting the sale of commercial cannabis edibles (e.g. THC containing candies, baked goods, and drinks). In this study we took advantage of this phased roll out of legal cannabis to understand the impact of legalization on cannabis exposures or poisonings in children aged 0-9 years and the contribution of different types of cannabis products to these events. (more…)
Author Interviews, Cannabis, Neurology, Pediatrics / 15.12.2021

MedicalResearch.com Interview with: Rayyan Raja Zafar BSc. MSc. MRSB. Medical Research Council Doctoral Training Partnership (MRC DTP) PhD Candidate Centre for Psychedelic research & Neuropsychopharmacology Division of Psychiatry Department of Brain Sciences, Faculty of Medicine Professor David Nutt DM, FRCP, FRCPsych, FSB, FMedSci Faculty of Medicine, Department of Brain Sciences The Edmond J Safra Chair in Neuropsychopharmacology Imperial College London MedicalResearch.com: What is the background for this study? Response: Since 2018 medical cannabis prescription has become legal in the UK for patients to access. In spite of this legal change less than 3 NHS prescriptions have been made available and access to whole-plant medical cannabis products has been restricted largely to private prescriptions with very few clinicians prescribing such products. There has been a lot of anecdotal and real world evidence of the value of whole-plant medical cannabis in children suffering with treatment resistant epilepsy. (more…)
Author Interviews, Cannabis, Fertility / 30.11.2021

MedicalResearch.com Interview with: Kanako Hayashi PhD Associate Professor Associate Director, Center for Reproductive Biology Washington State University MedicalResearch.com: What is the background for this study? Response: There have been several correlative reports showing statistical associations between cannabis use and low sperm counts, dysregulated menstruation, abnormal placentation, preterm birth, stillbirth and offspring psychosis etc. However, the long-term consequences of cannabis use on reproductive functions and how it might impact the next generation have not been examined. In the present study, we examined the generational effects of cannabis vapor exposure on male reproductive function. Vaporization is the most common route of cannabis administration in humans. Therefore, in order to understand the generational effects of cannabis exposure on male reproductive functions, the present study was performed using an inhalation method as an administration route, by which adult male mice were exposed to dry cannabis plants to assess the toxicological effects of cannabis on F0, F1 and F2 male reproductive functions. (more…)
Author Interviews, Cannabis, JAMA, Pediatrics / 25.10.2021

MedicalResearch.com Interview with: Carmen Lim BSc(Hons), MSc, CStat PhD Candidate National Centre for Youth Substance Use Research Faculty of Health and Behavioural Sciences The University of Queensland Brisbane Australia MedicalResearch.com: What is the background for this study? What are the main findings? Response: This review has systematically summarized the trends and products used for cannabis vaping using 17 studies published globally between Jan 1, 2003 and August 19, 2020. The pooled prevalence has increased for lifetime use (6.1% in 2013 to 13.6% in 2020), past-year use (7.2% in 2017 to 13.2% in 2020) and past-month use (1.6% in 2013 to 8.4% in 2020). Adolescents' preference for cannabis products may be shifting from less potent products (e.g., herbal cannabis) to highly potent vape oil and concentrates. (more…)
Author Interviews, Cannabis / 17.09.2021

MedicalResearch.com Interview with: Sam Craft Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King’s College London, London UK MedicalResearch.com: What is the background for this study? Response: Synthetic cannabinoid receptor agonists (SCRAs, also known as Spice or K2) are a group of synthetic drugs originally produced to mimic the effects of cannabis. As they are often more accessible or cheaper and cannot be detected on drugs tests, SCRAs may be used as an alternative to cannabis. However, although they act on the same receptors – cannabinoid receptor type 1 and 2 (CBR1; CBR2) – SCRAs are far more potent than cannabis which may make them more addictive and increase the severity of withdrawal (unpleasant symptoms experienced after cessation of a drug which has been used in large amounts for a long period of time) As part of the Global Drug Survey, in this study we asked participants who use both SCRAs and cannabis to compare their effects across different measures which indicate how likely a drug is to result in long-term harm. For example, how severe withdrawal symptoms are and how long the effects last. We also asked participants which withdrawal symptoms they experienced when attempting to stop.  (more…)
Author Interviews, Cannabis, JAMA / 07.09.2021

MedicalResearch.com Interview with: Mark Anderson, Ph.D. Associate Professor Department of Agricultural Economics and Economics Montana State University, IZA, and NBER  MedicalResearch.com: What is the background for this study? Response: In a previous study that was published in JAMA Pediatrics, we used Youth Risk Behavior Survey (YRBS) data and found that the adoption of recreational marijuana laws (RMLs) was associated with an 8% decrease in the odds of marijuana use among high school students.  This earlier study, however, had pre-legalization and post-legalization data from only 7 states and pre- and post-recreational sales data from only 3 states, calling into question the generalizability of our findings. (more…)
Author Interviews, Autism, Cannabis, JAMA, Pediatrics / 28.05.2021

MedicalResearch.com Interview with: Daimei Sasayama, M.D., Ph.D. Department of Psychiatry Shinshu University MedicalResearch.com: What is the background for this study? Response: The diagnosis of autism spectrum disorder (ASD) is increasing worldwide. A 2016 US survey reported a prevalence of 1.85% in 8-year-olds, and a birth cohort study in Denmark reported that the future cumulative incidence of ASD could exceed 2.8%. Our recent regional cohort study in Japan reported an even higher cumulative incidence of 3.1%. So we examined whether the cumulative incidence in our regional cohort represents the nationwide incidence in Japan.  (more…)
Accidents & Violence, Author Interviews, Cannabis, CMAJ / 06.04.2021

MedicalResearch.com Interview with: Sarah Windle, MPH PhD Student in Epidemiology Department of Epidemiology, Biostatistics, and Occupational Health McGill University (Montréal, Québec, Canada) MedicalResearch.com: What is the background for this study? Response: Concerns have been raised about the potential for increases in impaired driving following the legalization of recreational cannabis use in Canada in October 2018. Data from Statistics Canada suggest that cannabis use in the previous three months increased among adults (15 and older) from 14% before legalization in 2018 to 17% in 2019. Among those users with a driver’s license, 13% reported driving within two hours of cannabis use. While this proportion remained the same before and after legalization, this indicates that the absolute number of individuals who reported driving within two hours of use has increased following legalization (due to an increase in the number of users). (more…)
Author Interviews, Cannabis, JAMA, OBGYNE, Pediatrics / 08.03.2021

MedicalResearch.com Interview with: Erica M. Wymore, MD MPH Assistant Professor, Neonatal- Perinatal Medicine Department of Pediatrics, Section of Neonatology University of Colorado School of Medicine Children's Hospital Colorado Maya Bunik, MD, MPH  |  Professor, Pediatrics Medical Director, Child Health Clinic, Primary Care  |  Breastfeeding Management Clinic Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS) School of Medicine| University of Colorado Anschutz Medical Campus Children's Hospital Colorado MedicalResearch.com: What is the background for this study? Response: Marijuana legalization has been increasing in the United States, with increasing consumption of marijuana products. Currently, the American Academy of Pediatrics (AAP), American College of Obstetricians and Gynecologists (ACOG) and Academy of Breastfeeding Medicine (ABM) do not recommend marijuana use during pregnancy or lactation due to concerning though limited data on the effects of perinatal marijuana exposure. As there has been increasing prevalence of women using marijuana during pregnancy due to legalization and perceptions of safety, we sought to determine the duration of THC excretion in breast milk among women who had evidence of marijuana use at delivery and abstained post-partum.  (more…)
Author Interviews, Blood Pressure - Hypertension, Cannabis / 10.02.2021

MedicalResearch.com Interview with: Ran Abuhasira MD, PhD student Cannabis Clinical Research Institute and Clinical Research Center Soroka University Medical Center, and Faculty of Health Sciences Ben-Gurion University of the Negev Beer Sheva, Israel MedicalResearch.com: What is the background for this study? What are the main findings? cannabis marijuana weed pot Response: The background for the study is the steady rise of cannabis use as a therapeutic in Israel and in many countries around the world. This largest increasing population of patients treated with medical cannabis is the older adults. However, very little data was published about cannabis treatment in older adults, and specifically about the cardiovascular and metabolic implications. T he main finding of the study is that cannabis treatment for 3 months was associated with a reduction in both systolic and diastolic blood pressure values, as measured by consequent 24-hours ABPM tests. In addition, no significant changes were found in blood lipids profile, hemoglobin A1C, fasting insulin, C-reactive protein, kidney function tests, electrolytes, anthropometric measurements, and ECG parameters. (more…)
Author Interviews, Cannabis / 03.02.2021

MedicalResearch.com Interview with: Benjamin J. Warnick, PhD Assistant Professor of Entrepreneurship Carson College of Business Washington State University Vancouver MedicalResearch.com: What is the background for this study? Response: Popular culture has perpetuated a notion that cannabis users are more creative. Along these lines, some successful CEOs and entrepreneurs—like Steve Jobs, for example—have claimed that cannabis use has benefitted their creativity at work. Despite such claims and increased legalization and use of cannabis, the implications of cannabis use for entrepreneurs’ creativity has yet to be rigorously tested. My coauthors and I were very intrigued to dive into the implications of cannabis use for entrepreneurs, whether good or bad. This seemed all the more relevant given the increasing legalization, destigmatization, and use of cannabis.  (more…)
Author Interviews, BMJ, Cannabis, Opiods, Yale / 29.01.2021

MedicalResearch.com Interview with: Balázs Kovács PhD Associate Professor of Organizational Behavior Yale School of Management MedicalResearch.com: What is the background for this study? Response: Our study looks at the association between the prevalence of legal cannabis stores, called “dispensaries”, and opioid-related mortality rates in the U.S.  We find that higher cannabis dispensary counts are associated with reduced opioid-related mortality rates.   We find this relationship holds for both medical dispensaries, which only serve patients who have a state-approved medical card or doctor’s recommendation, as well as for recreational dispensaries, which sell to adults 21 years and older.  The statistical associations we find appears most pronounced with the class of opioids that includes fentanyl and its analogs.  (more…)
Author Interviews, Cannabis, UCSF / 15.01.2021

MedicalResearch.com Interview with: Eric R. Pedersen, Ph.D. Adjunct Behavioral Scientist, RAND Associate Professor of Psychiatry and Behavioral Sciences Keck School of Medicine University of Southern California MedicalResearch.com: What is the background for this study? Response: In November of 2016, CA voted to legalize cannabis for sale and possession to adults 21 and older for recreational use. It wasn’t until January of 2018 that stores in most parts of LA County (we call these “outlets”) were legally able to begin selling recreational cannabis. We were collecting data from about 2,500 young adults in LA County as part of a longitudinal study (Principal Investigator Elizabeth D’Amico at RAND) and were able to look at cannabis use and intentions assessed at a period prior to the opening of the recreational cannabis outlets (pre-January 2018) to a period when those outlets were open (after January 2018). It has been suggested that once cannabis was more available for recreational purchase (and not just for medical purposes among those enrolled in CA’s medical marijuana program), use of cannabis among young adults would increase.  (more…)